Baseline characteristics of the patients
Variable . | Deferoxamine only . | Deferiprone-switched . | P . |
|---|---|---|---|
| No. patients | 359 | 157 | — |
| Sex, no. (%) | .85 | ||
| Male | 184 (51) | 79 (50) | |
| Female | 175 (49) | 78 (50) | |
| Birth cohort, no. (%) | .26 | ||
| 1970-1979 | 234 (65) | 105 (67) | |
| 1980-1989 | 107 (30) | 49 (31) | |
| 1990-1993 | 18 (5) | 3 (2) | |
| Median age at diagnosis, y (range) | 0.64 (0.02-3.17) | 0.55 (0-2.97) | .20 |
| Median age at study entry, y (range) | 17.4 (1.58-25.1) | 17.5 (2.45-24.9) | .71 |
| Median time from first transfusion to entry, y (range) | 16.3 (1.19-24.8) | 16.6 (1.72-24.5) | .62 |
| Median serum ferritin in 1995, μg/L (range)* | 1461 (160-9458) | 1870 (532-10632) | < .001 |
| Ferritin level in 1995, no. (%) | .003 | ||
| Less than 1000 μg/L | 87 (28) | 19 (14) | |
| 1000-2500 μg/L | 160 (51) | 74 (55) | |
| More than 2500 μg/L | 66 (21) | 42 (31) |
Variable . | Deferoxamine only . | Deferiprone-switched . | P . |
|---|---|---|---|
| No. patients | 359 | 157 | — |
| Sex, no. (%) | .85 | ||
| Male | 184 (51) | 79 (50) | |
| Female | 175 (49) | 78 (50) | |
| Birth cohort, no. (%) | .26 | ||
| 1970-1979 | 234 (65) | 105 (67) | |
| 1980-1989 | 107 (30) | 49 (31) | |
| 1990-1993 | 18 (5) | 3 (2) | |
| Median age at diagnosis, y (range) | 0.64 (0.02-3.17) | 0.55 (0-2.97) | .20 |
| Median age at study entry, y (range) | 17.4 (1.58-25.1) | 17.5 (2.45-24.9) | .71 |
| Median time from first transfusion to entry, y (range) | 16.3 (1.19-24.8) | 16.6 (1.72-24.5) | .62 |
| Median serum ferritin in 1995, μg/L (range)* | 1461 (160-9458) | 1870 (532-10632) | < .001 |
| Ferritin level in 1995, no. (%) | .003 | ||
| Less than 1000 μg/L | 87 (28) | 19 (14) | |
| 1000-2500 μg/L | 160 (51) | 74 (55) | |
| More than 2500 μg/L | 66 (21) | 42 (31) |
— indicates not applicable.
n = 313 for deferoxamine only, and n = 135 for deferiprone-switched